Segesterone acetate/ethinylestradiol
Combination hormonal birth control
From Wikipedia, the free encyclopedia
Segesterone acetate/ethinylestradiol (EE/SGA), sold under the brand name Annovera among others, is a contraceptive vaginal ring and combined form of hormonal birth control which contains segesterone acetate, a progestin; and ethinylestradiol, an estrogen.[3][5][6] It contains 17.4 mg ethinylestradiol and 103 mg segesterone acetate, releases an average of 13 μg ethinylestradiol and 0.15 mg segesterone acetate per day.[3][7]
| |
 | |
| Combination of | |
|---|---|
| Segesterone acetate | Progestogen |
| Ethinylestradiol | Estrogen |
| Clinical data | |
| Trade names | Annovera |
| Other names | EE/SGA; EE/SA |
| AHFS/Drugs.com | Professional Drug Facts |
| MedlinePlus | a604032 |
| License data | |
| Routes of administration | Intravaginal |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| KEGG | |
The ring is inserted into the vagina and left for 21 days, then removed, washed and stored for seven days, during which the user experiences a period (withdrawal bleeding.) This can be repeated thirteen times, for one full year of use.[8] Unlike NuvaRing, another vaginal ring contraceptive, the combination ring does not need to be refrigerated before being dispensed and can be stored at room temperature up to 30 degrees Celsius.[3]
The medication was developed by the Population Council, an international non-profit organization, and licensed to TherapeuticsMD.[7] It was approved for medical use in the United States in August 2018,[9] and in Canada in December 2024.[1]
